Catabasis Pharmaceuticals
| Region | Nordamerika |
| ISIN | US14875P2065 |
| Sektor | Biotechnologie |
| Website | https://www.catabasis.com/ |
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
| Titel | Autor | Datum |
|---|---|---|
|
Der Tenbagger-Kandidat für 2020!
|
sharedeals | vor über 5 Jahren |
|
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare |
sharedeals | vor über 6 Jahren |
| Titel | Datum |
|---|---|
| Bumi Armada, MISC, Zetrix, Heitech Padu, Kelington, Kim Hin, Hibiscus, Johor Plantations Group, Ajiya, Pekat, Kimlun, Jiankun & Farm Price | vor 27 Tagen |
| MISC, Bumi Armada call off merger proposal | vor 27 Tagen |
| DNV awards GASA approval to joint LCO2 carrier design by MOL, MISC, PETRONAS CCS Ventures and SDARI | vor ungefähr einem Monat |
| MOL, MISC and PETRONAS form joint venture to advance cross-border CO2 transportation | vor ungefähr 2 Monaten |
| Petronas, MISC and MOL debut LCO2 carrier JV | vor ungefähr 2 Monaten |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| Cannabis Wheaton Income (2 Artikel) | |
| BYD Company (1 Artikel) | |
| CBLT (1 Artikel) | |
| Celgene (1 Artikel) | |
| Alle anzeigen | |